Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.56
NAS:CORT's Cash-to-Debt is ranked lower than
65% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. NAS:CORT: 2.56 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CORT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 1135.78 Max: No Debt
Current: 2.56
Equity-to-Asset 0.50
NAS:CORT's Equity-to-Asset is ranked lower than
66% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. NAS:CORT: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CORT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.51 Max: 0.89
Current: 0.5
-0.1
0.89
Interest Coverage 2.94
NAS:CORT's Interest Coverage is ranked lower than
94% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CORT: 2.94 )
Ranked among companies with meaningful Interest Coverage only.
NAS:CORT' s Interest Coverage Range Over the Past 10 Years
Min: 2.94  Med: N/A Max: No Debt
Current: 2.94
Piotroski F-Score: 7
Altman Z-Score: 13.38
Beneish M-Score: -2.97
WACC vs ROIC
10.38%
136.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 9.41
NAS:CORT's Operating Margin % is ranked higher than
75% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. NAS:CORT: 9.41 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CORT' s Operating Margin % Range Over the Past 10 Years
Min: -69827.59  Med: -1818.64 Max: 9.41
Current: 9.41
-69827.59
9.41
Net Margin % 6.21
NAS:CORT's Net Margin % is ranked higher than
73% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. NAS:CORT: 6.21 )
Ranked among companies with meaningful Net Margin % only.
NAS:CORT' s Net Margin % Range Over the Past 10 Years
Min: -69537.93  Med: -1775.79 Max: 6.21
Current: 6.21
-69537.93
6.21
ROE % 20.64
NAS:CORT's ROE % is ranked higher than
89% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. NAS:CORT: 20.64 )
Ranked among companies with meaningful ROE % only.
NAS:CORT' s ROE % Range Over the Past 10 Years
Min: -356.04  Med: -113.3 Max: 20.64
Current: 20.64
-356.04
20.64
ROA % 8.25
NAS:CORT's ROA % is ranked higher than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. NAS:CORT: 8.25 )
Ranked among companies with meaningful ROA % only.
NAS:CORT' s ROA % Range Over the Past 10 Years
Min: -124.18  Med: -87.4 Max: 8.25
Current: 8.25
-124.18
8.25
ROC (Joel Greenblatt) % 265.76
NAS:CORT's ROC (Joel Greenblatt) % is ranked higher than
96% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. NAS:CORT: 265.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CORT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -370585.71  Med: -49033.54 Max: 265.76
Current: 265.76
-370585.71
265.76
3-Year Revenue Growth Rate 135.50
NAS:CORT's 3-Year Revenue Growth Rate is ranked higher than
95% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:CORT: 135.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CORT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 135.5
0
230.2
3-Year EBITDA Growth Rate -57.00
NAS:CORT's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NAS:CORT: -57.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CORT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -16.85 Max: 3
Current: -57
0
3
3-Year EPS without NRI Growth Rate -47.30
NAS:CORT's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:CORT: -47.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CORT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: -11.45 Max: 6.6
Current: -47.3
-47.3
6.6
GuruFocus has detected 3 Warning Signs with Corcept Therapeutics Inc $NAS:CORT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CORT Guru Trades in Q1 2016

First Eagle Investment 395,670 sh (+31.89%)
Paul Tudor Jones 28,799 sh (+6.27%)
Joel Greenblatt Sold Out
Jim Simons 191,400 sh (-58.43%)
» More
Q2 2016

CORT Guru Trades in Q2 2016

Joel Greenblatt 15,024 sh (New)
Jim Simons 310,600 sh (+62.28%)
Paul Tudor Jones 28,449 sh (-1.22%)
First Eagle Investment 223,935 sh (-43.40%)
» More
Q3 2016

CORT Guru Trades in Q3 2016

Jim Simons 560,000 sh (+80.30%)
Joel Greenblatt 20,908 sh (+39.16%)
Paul Tudor Jones 23,564 sh (-17.17%)
First Eagle Investment 125,000 sh (-44.18%)
» More
Q4 2016

CORT Guru Trades in Q4 2016

Jim Simons 1,507,500 sh (+169.20%)
Joel Greenblatt 38,010 sh (+81.80%)
Paul Tudor Jones Sold Out
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:XLRN, NAS:RGEN, OTCPK:PFSCF, OTCPK:BPMUF, NAS:AMRN, NAS:INSM, NAS:ALDR, NAS:INSY, NAS:FOLD, NAS:ACOR, NAS:ZIOP, NAS:AMAG, NAS:VSAR, NYSE:EBS, OTCPK:SXMDF, NAS:ANIK, NAS:PGNX, NAS:INVA, OTCPK:BVNRY, NAS:CLLS » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders associated with thesteroid hormone cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Ratios

vs
industry
vs
history
PE Ratio 227.75
CORT's PE Ratio is ranked lower than
95% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. CORT: 227.75 )
Ranked among companies with meaningful PE Ratio only.
CORT' s PE Ratio Range Over the Past 10 Years
Min: 132.75  Med: 207 Max: 601
Current: 227.75
132.75
601
PE Ratio without NRI 227.75
CORT's PE Ratio without NRI is ranked lower than
95% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. CORT: 227.75 )
Ranked among companies with meaningful PE Ratio without NRI only.
CORT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 132.75  Med: 207 Max: 601
Current: 227.75
132.75
601
Price-to-Owner-Earnings 116.81
CORT's Price-to-Owner-Earnings is ranked lower than
88% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. CORT: 116.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CORT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 68.08  Med: 106.15 Max: 667.78
Current: 116.81
68.08
667.78
PB Ratio 32.28
CORT's PB Ratio is ranked lower than
95% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. CORT: 32.28 )
Ranked among companies with meaningful PB Ratio only.
CORT' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 12.12 Max: 86.18
Current: 32.28
1.82
86.18
PS Ratio 14.12
CORT's PS Ratio is ranked lower than
60% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. CORT: 14.12 )
Ranked among companies with meaningful PS Ratio only.
CORT' s PS Ratio Range Over the Past 10 Years
Min: 7.18  Med: 158.06 Max: 1990
Current: 14.12
7.18
1990
Price-to-Free-Cash-Flow 57.31
CORT's Price-to-Free-Cash-Flow is ranked lower than
76% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. CORT: 57.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CORT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 33.4  Med: 60.77 Max: 188.93
Current: 57.31
33.4
188.93
Price-to-Operating-Cash-Flow 56.95
CORT's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. CORT: 56.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.19  Med: 60.75 Max: 182.41
Current: 56.95
33.19
182.41
EV-to-EBIT 143.91
CORT's EV-to-EBIT is ranked lower than
93% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. CORT: 143.91 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.5  Med: -5.65 Max: 488.9
Current: 143.91
-160.5
488.9
EV-to-EBITDA 141.83
CORT's EV-to-EBITDA is ranked lower than
93% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. CORT: 141.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -168  Med: -5.7 Max: 436.4
Current: 141.83
-168
436.4
Current Ratio 1.89
CORT's Current Ratio is ranked lower than
71% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. CORT: 1.89 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 7.21 Max: 37.77
Current: 1.89
1.89
37.77
Quick Ratio 1.81
CORT's Quick Ratio is ranked lower than
67% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. CORT: 1.81 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 7.21 Max: 37.77
Current: 1.81
1.81
37.77
Days Inventory 378.89
CORT's Days Inventory is ranked lower than
90% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. CORT: 378.89 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 378.89  Med: 1093.61 Max: 2487.36
Current: 378.89
378.89
2487.36
Days Sales Outstanding 41.48
CORT's Days Sales Outstanding is ranked higher than
68% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CORT: 41.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.48  Med: 48.08 Max: 61.48
Current: 41.48
41.48
61.48
Days Payable 845.13
CORT's Days Payable is ranked higher than
99% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. CORT: 845.13 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 3428.94 Max: 15257.8
Current: 845.13
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.20
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. CORT: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -21.3 Max: -3.2
Current: -3.2
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 60.73
CORT's Price-to-Net-Cash is ranked lower than
92% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. CORT: 60.73 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CORT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.36 Max: 376
Current: 60.73
2.5
376
Price-to-Net-Current-Asset-Value 36.44
CORT's Price-to-Net-Current-Asset-Value is ranked lower than
90% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CORT: 36.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 6.34 Max: 93.33
Current: 36.44
2.43
93.33
Price-to-Tangible-Book 32.54
CORT's Price-to-Tangible-Book is ranked lower than
93% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CORT: 32.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31  Med: 6.3 Max: 82.35
Current: 32.54
2.31
82.35
Price-to-Median-PS-Value 0.09
CORT's Price-to-Median-PS-Value is ranked higher than
98% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. CORT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.37 Max: 8.06
Current: 0.09
0.05
8.06
Price-to-Graham-Number 18.22
CORT's Price-to-Graham-Number is ranked lower than
95% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. CORT: 18.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CORT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 13  Med: 18.37 Max: 23.74
Current: 18.22
13
23.74
Earnings Yield (Greenblatt) % 0.68
CORT's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. CORT: 0.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 0.65 Max: 1.2
Current: 0.68
0.2
1.2

More Statistics

Revenue (TTM) (Mil) $72.48
EPS (TTM) $ 0.04
Beta1.07
Short Percentage of Float7.99%
52-Week Range $3.78 - 10.00
Shares Outstanding (Mil)111.03
» More Articles for CORT

Headlines

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : February 14, 2017 Feb 14 2017
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Feb 13 2017
Coverage initiated on Corcept Therapeutics by Ladenburg Thalmann Feb 02 2017
Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT Jan 31 2017
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and... Jan 30 2017
Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close Jan 30 2017
Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance... Jan 23 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US :... Jan 11 2017
Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : December 23, 2016 Dec 23 2016
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US :... Dec 22 2016
Corcept Korlym Positive in Phase I/II Breast Cancer Study Dec 12 2016
Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio? Dec 10 2016
Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin... Dec 10 2016
Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session Nov 11 2016
CORCEPT THERAPEUTICS INC Financials Nov 05 2016
Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance Nov 02 2016
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Nov 02 2016
Edited Transcript of CORT earnings conference call or presentation 1-Nov-16 9:00pm GMT Nov 02 2016
Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)